Stem cell therapies for reversing vision loss

Citation

Higuchi, Akon and Kumar, S. Suresh and Benelli, Giovanni and Alarfaj, Abdullah A. and Munusamy, Murugan A. and Umezawa, Akihiko and Murugan, Kadarkarai (2017) Stem cell therapies for reversing vision loss. Trends in Biotechnology, 35 (11). 1102 - 1117. ISSN 0167-7799; ESSN: 1879-3096

Abstract

Current clinical trials that evaluate human pluripotent stem cell (hPSC)-based therapies predominantly target treating macular degeneration of the eyes because the eye is an isolated tissue that is naturally weakly immunogenic. Here, we discuss current bioengineering approaches and biomaterial usage in combination with stem cell therapy for macular degeneration disease treatment. Retinal pigment epithelium (RPE) differentiated from hPSCs is typically used in most clinical trials for treating patients, whereas bone marrow mononuclear cells (BMNCs) or mesenchymal stem cells (MSCs) are intravitreally transplanted, undifferentiated, into patient eyes. We also discuss reported negative effects of stem cell therapy, such as patients becoming blind following transplantation of adipose-derived stem cells, which are increasingly used by 'stem-cell clinics'.

Download File

Preview

Text (Abstract)
Stem cell therapies for reversing vision loss.pdf
Download (4kB) | Preview

Additional Metadata

Item Type:	Article
Divisions:	Faculty of Medicine and Health Science
Publisher:	Cell Press
Keywords:	Stem Cell; Human Pluripotent Stem Cell (hPSC); Transplants; Human induced PSC (iPSC)
Depositing User:	Mohd Hafiz Che Mahasan
Date Deposited:	26 Sep 2018 01:50
Last Modified:	26 Sep 2018 01:50
URI:	http://psasir.upm.edu.my/id/eprint/63289
Statistic Details:	View Download Statistic

Actions (login required)

View Item